Page last updated: 2024-12-06

1,2-distearoyllecithin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

1,2-distearoyllecithin, also known as DSPC, is a synthetic phospholipid composed of two stearic acid molecules esterified to the glycerol backbone of phosphatidylcholine. It is a common component of model membranes and liposomes used in research. DSPC is often used to mimic the lipid bilayer structure of cell membranes. Its importance lies in its ability to form stable, highly ordered lipid bilayers. This allows researchers to study various membrane properties such as fluidity, permeability, and interactions with proteins. DSPC is widely used in drug delivery research due to its ability to encapsulate and deliver various therapeutic agents. It is also used in cosmetic formulations for its moisturizing and skin-conditioning properties.'

Cross-References

ID SourceID
PubMed CID65146
CHEMBL ID113644
SCHEMBL ID565771
MeSH IDM0056861

Synonyms (50)

Synonym
D-7850
choline, hydroxide, dihydrogen phosphate, inner salt, ester with 1,2-distearin
97281-48-6
hydro soy pc
2,3-di(octadecanoyloxy)propyl 2-(trimethylazaniumyl)ethyl phosphate
CHEMBL113644
4539-70-2
unii-eag959u971
1,2-distearoylphosphatidylcholine
1,2-distearoyllecithin
distearoyl-dl-phosphatidylcholine
dioctadecanoyllecithin
4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxooctadecyl)oxy)-3,5,9-trioxa-4-phosphahepta cosan-1-aminium hydroxide, inner salt, 4-oxide
3,5,9-trioxa-4-phosphaheptacosan-1-aminium, 4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxooctadecyl)oxy)-, hydroxide, inner salt, 4-oxide
4-hydroxy-n,n,n-trimethyl-10-oxo-7-((1-oxooctadecyl)oxy)-3,5,9-trioxa-4-phosphaheptacosan-1-aminium hydroxide, inner salt, 4-oxide
eag959u971 ,
1,2-distearoyl-rac-glycero-3-phosphocholine
816-93-3
FT-0627777
FT-0627664
einecs 306-549-5
unii-qhq97hf0py
qhq97hf0py ,
SCHEMBL565771
distearoylphosphatidylcholine, dl-
1,2-distearoyl-dl-phosphatidylcholine
dspc dl-
dioctadecanoyl phosphatidylcholine
1,2-distearoyl phosphatidylcholine, (+/-)-
dl-beta,gamma-distearoyl-alpha-lecithin
mfcd00067532
dl-,-distearoyl--lecithin
FT-0759476
dl-alpha-phosphatidylcholine, distearoyl
2,3-bis(stearoyloxy)propyl (2-(trimethylammonio)ethyl) phosphate
DB14099
2,3-bis(stearoyloxy)propyl 2-(trimethylammonio)ethyl phosphate
4,4-bis[2-(2-methoxyphenyl)ethenyl]-1,1-biphenyl
DTXSID20963380
dl-distearoylphosphatidylcholine
Q27277073
A924644
XDA28148
PD085655
2,3-bis(stearoyloxy)propyl(2-(trimethylammonio)ethyl)phosphate
phosphatidylcholines,soya, hydrogenated
EN300-7414588
(2-{[2,3-bis(octadecanoyloxy)propyl phosphonato]oxy}ethyl)trimethylazanium
3,5,9-trioxa-4-phosphaheptacosan-1-aminium,4-hydroxy-n,n,n-trimethyl-10-oxo-7-[(1-oxooctadecyl)oxy]-, inner salt,4-oxide, (7r)-
SY057807

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"It is well established that the circulation half-life of liposomes increases with increasing dose."( Influence of dose on liposome clearance: critical role of blood proteins.
Chonn, A; Cullis, PR; Oja, CD; Semple, SC, 1996
)
0.29
"We have determined the pharmacokinetics of liposomal vincristine, in a Lewis lung carcinoma solid tumor model in mice, with the aim of differentiating the contribution of liposomal and nonliposomal (released from liposomes) drug pools to the overall pharmacokinetic profile."( Liposomal and nonliposomal drug pharmacokinetics after administration of liposome-encapsulated vincristine and their contribution to drug tissue distribution properties.
Krishna, R; Mayer, LD; St Onge, G; Webb, MS, 2001
)
0.31

Compound-Compound Interactions

ExcerptReferenceRelevance
" Modest modulation of P-glycoprotein-mediated MDR was observed in the murine P388/ADR solid tumor model when PSC 833 was administered with free DOX at the MTD."( Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna, R; Mayer, LD, 1997
)
0.3

Bioavailability

ExcerptReferenceRelevance
" One way of prolonging the bioavailability of 99Tcm-MIBI is to use liposomes which do not affect its accumulation in tumour cells."( Uptake of liposome-encapsulated 99Tcm-MIBI by sensitive and multidrug-resistant tumour cell lines.
Benazzouz, F; Cordobes, MD; de Beco, V; Moretti, JL; Starzec, A, 1999
)
0.3
" Its stability as well as bioavailability can be increased by making prodrugs."( Characterization of lipophilic gemcitabine prodrug-liposomal membrane interaction by differential scanning calorimetry.
Castelli, F; Cattel, L; Ceruti, M; Rocco, F; Sarpietro, MG,
)
0.13
" Despite the fact that DSPC-based and pegylated-arsonoliposomes have better bioavailability compared to PC-based ones, their in vitro activity is lower than that of PC-based arsonoliposomes, indicating the importance of arsonoliposome lipid composition on their trypanocidal activity and suggesting that further arsonoliposome structure design is required to overcome these disadvantages."( Trypanocidal activity of arsonoliposomes: effect of vesicle lipid composition.
Antimisiaris, SG; Ioannou, PV; Klepetsanis, P; Loiseau, PM; Zagana, P, 2007
)
0.34
" The observed structural changes may have important consequences for the bioavailability of protein/peptide drugs bound to, or embedded in, the liposome membranes."( Structural effects caused by spray- and freeze-drying of liposomes and bilayer disks.
Edwards, K; Mahlin, D; Wessman, P, 2010
)
0.36
" A small amount of carrier phospholipid significantly increases the rate and the extent of dissolution, which may increase the bioavailability of ibuprofen."( Ibuprofen-phospholipid solid dispersions: improved dissolution and gastric tolerance.
Brausch, JF; Hussain, MD; Saxena, V; Talukder, RM, 2012
)
0.38
"This study aimed to design the chitosan coated liposomes of alendronate and optimize their in vitro/in vivo characteristics to improve the bioavailability as well as potentially to reduce the mucosal irritation of alendronate."( Improved oral bioavailability of alendronate via the mucoadhesive liposomal delivery system.
Ha, DH; Han, HK; Shin, HJ, 2012
)
0.38
"Phospholipid vesicles (liposomes) formed in pharmaceutically acceptable nonaqueous polar solvents such as propylene glycol are of interest in drug delivery because of their ability to improve the bioavailability of drugs with poor aqueous solubility."( Stabilization of distearoylphosphatidylcholine lamellar phases in propylene glycol using cholesterol.
Ara, N; Barlow, DJ; Harvey, RD; Heenan, RK; Lawrence, MJ; Quinn, PJ, 2013
)
0.39
" In the present study, an attempt was made to study the brain bioavailability of commonly used anti-Alzheimer drug donepezil (DNP) liposomal formulation by intranasal route in rats."( Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil.
Al Asmari, AK; Fatani, A; Tariq, M; Ullah, Z, 2016
)
0.43
" In mice, orally delivered liquid and lyophilized Mef-Lipo displayed comparable absorption with bioavailability (BA) of 81-86%, while the absorption of the standard Mef suspension was significantly lower with BA of 70% and 20% decreased maximal plasma concentration and area under the curve."( Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes.
Chen, WC; Diako, C; Li, SD; Ross, CF; Tang, WH; Tang, WL, 2017
)
0.46

Dosage Studied

ExcerptRelevanceReference
" PSC 833 in single and multiple dosage regimens over a 15-day study period."( Liposomal doxorubicin circumvents PSC 833-free drug interactions, resulting in effective therapy of multidrug-resistant solid tumors.
Krishna, R; Mayer, LD, 1997
)
0.3
"A novel dialysis adapter has been developed for USP apparatus 4 for in vitro release testing of dispersed system dosage forms."( A novel USP apparatus 4 based release testing method for dispersed systems.
Bhardwaj, U; Burgess, DJ, 2010
)
0.36
" In this study, we developed a novel microbubble carrying 10-HCPT which only needs a particularly low single dose of injection (4-6 mg) for tumor therapy in clinical application, therefore, the required high dosing of drug loaded MBs for ultrasound mediated drug delivery is not necessary."( Ultrasound triggered drug release from 10-hydroxycamptothecin-loaded phospholipid microbubbles for targeted tumor therapy in mice.
Li, P; Lin, Y; Ran, H; Ren, J; Tan, J; Wang, Z; Zhang, Q; Zheng, Y, 2012
)
0.38
" The dosage form for Mef is mostly available as adult tablets, and thus children under the age of 5 suffer from poor medication adherence."( Development of a Rapidly Dissolvable Oral Pediatric Formulation for Mefloquine Using Liposomes.
Chen, WC; Diako, C; Li, SD; Ross, CF; Tang, WH; Tang, WL, 2017
)
0.46
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID93758Inhibitory concentration against human rotavirus MO strain; No inhibition1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis of a novel sialic acid derivative (sialylphospholipid) as an antirotaviral agent.
AID204953Inhibitory concentration against Simian rotavirus SA-11 strain; No inhibition1997Journal of medicinal chemistry, Oct-10, Volume: 40, Issue:21
Synthesis of a novel sialic acid derivative (sialylphospholipid) as an antirotaviral agent.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (436)

TimeframeStudies, This Drug (%)All Drugs %
pre-199052 (11.93)18.7374
1990's118 (27.06)18.2507
2000's114 (26.15)29.6817
2010's141 (32.34)24.3611
2020's11 (2.52)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 8.65

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index8.65 (24.57)
Research Supply Index6.11 (2.92)
Research Growth Index4.77 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (8.65)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (0.22%)5.53%
Reviews2 (0.44%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other447 (99.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]